Print Friendly Page

Protocol No. UW17078

Principal Investigator Witek, Matthew

Phase N/A

Age Group Adult

Scope Local

Sponsor Type Externally Peer-Reviewed; Institutional

Title PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

Objective The purpose of this imaging study is to find out if we can use PET/MRI scans that are obtained part way through chemotherapy and radiation therapy to predict how a patient's tumor will respond to therapy and in the future, use this information to better adapt treatments to individuals and their tumors.
PET/MRI scans is a newer technology. Both PET scans and MRI scans have been used for many years to image cancer patients. The University of Wisconsin has recently acquired an imaging scanner that can acquire PET and MRI images simultaneously.

Treatment A series of 3 PET/MRI scans will be done:
  • 1 scan before cancer therapy begins
  • 1 scans 2 weeks into therapy
  • 1 scan after therapy ends

  • Description PET/MRI assessment of early response in HPV(+) head and neck cancer patients

    Key Eligibility
  • Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil or base of tongue) Note: Cytologic diagnosis from a cervical lymph node (from a paraffin block, not from smears) is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage)
  • Clinically- or radiographically-evident measurable disease at the primary site(Removal of nodal disease is permitted as long as the primary tumor remains intact) Biopsy specimens from the primary or nodes measuring at least 3mm-5mm are required
  • Clinical stage III-IVB (T3N0, T1-3N1, T4aN0-3, T4bN0-3, T1-4N2, T1-4N3) disease
  • Zubrod Performance Status 0-1
  • Adequate bone marrow, hepatic, and renal function Does the patient have cancer considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip) nasopharynx, hypopharynx, or larynx or an unknown primary
  • Distant metastases or adenopathy below the clavicles
  • Gross total excision of both primary and nodal disease(This includes tonsillectomy, local excision of primary site and nodal excision that remove all clinically and radiographically evident disease)
  • No prior invasive malignancy (except nonmelanomatous skin cancer) unless disease free for a minimum of 3 years
  • Patient able to receive weekly cisplatin chemotherapy

  • Applicable Disease Sites Head and Neck

    Status Open

    Participating Institutions UW Hospital and Clinics